大面积烧伤患者持续输注头孢洛扎/他唑巴坦的药代动力学
本文报告两例大面积体表烧伤、疑似肾脏清除增强并合并难治性铜绿假单胞菌血流感染的患者,均以9 g/日持续输注头孢洛扎/他唑巴坦。两例游离头孢洛扎平均血浆浓度分别为41.6 mg/L和22.8 mg/L,均实现100%给药间期fT>4×MIC,血流感染均清除。
要点
- 大面积烧伤患者中头孢洛扎/他唑巴坦暴露存在显著个体差异。
- 持续输注可实现100%给药间期fT>4×MIC的药效学目标。
- 疑似肾脏清除增强时持续输注β-内酰胺类可作为主动策略。
核心结论
- 大面积体表烧伤患者中头孢洛扎/他唑巴坦暴露变异大,持续输注β-内酰胺类可作为药效学目标达成的主动策略。
- 两例患者持续输注头孢洛扎/他唑巴坦后血流感染均成功清除。
研究设计与样本
- 病例报告,纳入两例大面积体表烧伤、疑似肾脏清除增强且合并难治性铜绿假单胞菌血流感染的患者。
- 两例均接受头孢洛扎/他唑巴坦9 g/日持续输注。
主要发现
- 病例1和病例2的头孢洛扎/他唑巴坦MIC分别为8/4 μg/mL和4/4 μg/mL。
- 病例1和病例2的平均游离头孢洛扎血浆浓度分别为41.6 mg/L和22.8 mg/L。
- 两例均实现100%的24小时输注期间游离浓度超过4倍MIC(fT>4×MIC)。
- 两例血流感染均成功清除。
临床怎么用
- 对大面积烧伤合并疑似肾脏清除增强的患者,可考虑持续输注β-内酰胺类以优化药效学目标达成。
- 治疗药物监测有助于评估烧伤患者中头孢洛扎/他唑巴坦暴露的个体差异。
局限性
- 仅两例病例报告,结果不能外推至所有烧伤患者。
- 未报告给药调整的具体决策过程及长期临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Treatment of infections in patients with burn injuries is challenging due to altered antimicrobial pharmacokinetics. Continuous infusion β-lactam therapy may be a useful antimicrobial stewardship strategy to improve pharmacodynamic target attainment in this population. CASE SUMMARIES: This report highlights the use of continuous infusion ceftolozane/tazobactam (C/T) in two patients with extensive total body surface area (TBSA) burns, suspected augmented renal clearance (ARC), and bloodstream infections caused by Pseudomonas aeruginosa with difficult-to-treat resistance (DTR P. aeruginosa). Both patients received C/T 9 g/day via continuous infusion. Minimum inhibitory concentrations (MIC) of C/T were 8/4 and 4/4 μg/mL in Cases 1 and 2, respectively. DISCUSSION: Despite similar patient characteristics, average free plasma ceftolozane concentrations were 41.6 mg/L in Case 1 and 22.8 mg/L in Case 2. Measured free concentrations exceeded 4 times the MIC for 100% of each 24-h infusion (fT > 4xMIC), and bacteremia was successfully cleared in each case. CONCLUSION: These cases highlight the variability of drug exposure in patients with extensive TBSA burn injuries and support continuous infusion β-lactam therapy as a proactive strategy to optimize pharmacodynamic target attainment when pharmacokinetics are unpredictable.
引用
- Olivet JD, Amerson-Brown M, Calix JJ, et al. Pharmacokinetics of continuous infusion ceftolozane/tazobactam in two patients with extensive total body surface area burns. Pharmacotherapy. 2025. PMID: 40231834. doi:10.1002/phar.70019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。